Brokerages Set Cryoport, Inc. (NASDAQ:CYRX) Target Price at $12.29

Shares of Cryoport, Inc. (NASDAQ:CYRX) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $12.29.

Several brokerages have weighed in on CYRX. UBS Group boosted their price objective on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Guggenheim began coverage on shares of Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, Roth Mkm cut their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th.

Cryoport Trading Up 0.6 %

Shares of CYRX opened at $7.85 on Friday. The stock has a fifty day moving average price of $7.45 and a two-hundred day moving average price of $7.89. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The company has a market cap of $388.03 million, a price-to-earnings ratio of -2.32 and a beta of 1.62. Cryoport has a 52-week low of $5.32 and a 52-week high of $20.10.

Insider Transactions at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the sale, the director now owns 59,497 shares in the company, valued at $443,847.62. This represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,869 shares of company stock worth $735,673 in the last 90 days. Insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC grew its position in shares of Cryoport by 1,083,000.0% during the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after purchasing an additional 10,830 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Cryoport during the 3rd quarter valued at approximately $82,000. Hsbc Holdings PLC bought a new stake in Cryoport in the 2nd quarter worth approximately $92,000. Intech Investment Management LLC bought a new position in shares of Cryoport during the 3rd quarter valued at approximately $105,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Cryoport by 9.5% in the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after purchasing an additional 1,534 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.